All News
We don’t take medications either because we can’t or because we don’t want to. Robert Horne on #adherence #EULAR2019 https://t.co/YUdLCfGErV
Loreto Carmona 🖖 carmona_loreto ( View Tweet)
This was a great presentation - 36K ANA test, 7875 repeat ANAs (11% rheums 82% non-rheums) ~10% each went from Pos to Neg (or Neg to Pos) but only 5 new Rheumatic Dx made - incredibly low yield and low PPV https://t.co/Ng8Fg4k158
Dr. John Cush RheumNow ( View Tweet)
Tildrakizumab, an IL-12/p19 inhibitor, studied in 391 very active #PsA pts. Rx compared PBO vs 4 different doses and TIL showed superior ACR 20/50/70 responses (79.5%/52.6%/29.1% vs 24%PBO) and 80% PASI75 at wk24. #EULAR2019 LB0002 https://t.co/QKg0yDS28B
Dr. John Cush RheumNow ( View Tweet)
I am so sorry to be missing EULAR this yr but feeling better!!! Will be Skyping in to the satellite Friday discussing what really matters to patients!!! @CCalabreseDO @RheumNow #IL6 @arthdoc https://t.co/teXkmmeAuo
Leonard Calabrese LCalabreseDO ( View Tweet)
Turned up to #EULAR2019 and immediately ran into three other Australians (separately). We’re all over this joint! @dr_rachelblack @tuna0sashimi 🇦🇺🇦🇺 @RheumNow https://t.co/kM7IHKQykf
David Liew drdavidliew ( View Tweet)
Dr Jon Kay on “drift” of reference product. Lessons from Herceptin biosimilar development #eular2019 SP0014 https://t.co/uqWgYESe6N
Dr. John Cush RheumNow ( View Tweet)
DESIR 708 early TNFi naive axSpA finds only 36% started a TNFi & 49% switched to a 2nd TNFi & 47% to 3rd TNFi #EULAR2019 OP0012 https://t.co/5TMPofwRas
Dr. John Cush RheumNow ( View Tweet)
What happens when MTX-IR pts who don't respond to Adalimumab or Upadacitinib in Select compare RCT switch to other treatment? More switched out of adalimumab. Either group on average did well maybe switch to Upa a bit better but post hoc analysis. OP0029 #EULAR2019 @RheumNow https://t.co/sIG0kPPfNB
Janet Pope Janetbirdope ( View Tweet)
Ustekinumab in SLE, SLEDAI >=6 bilag 1A or 2B, ph2 results SRI-4 at w24 published. Sustained responses acc to SRI4, PGA, joint and CLASI to w48. Clasi even had higher response at w48. Those which switched to open label showed incremental improvement. Nice. #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
In a disease where there aren’t a lot of options, nintedanib reduces FVC rate of decline in SSc-ILD by >40%, independently of SSc subtype, antibody status, MMF exposure, just like it does in IPF.
Breathtaking results (so to speak) #EULAR2019 Distler for SENSCIS OP0017 @RheumNow https://t.co/eRsMxc7sdr https://t.co/LyqQf5apfx
David Liew drdavidliew ( View Tweet)
New molecular pathway in RA. #EULAR2019 @RheumNow https://t.co/woTApyicbl
Janet Pope Janetbirdope ( View Tweet)
Tofacitinib results in Corrona over 5 yrs vs bDMARDs. Not randomized but propensity scores showed no increased serious infection, CV events and VTE found in Tofa vs bDMARDs. Slightly more HZ. Good and reassuring safety. OP0028 #EULAR2019 @RheumNow https://t.co/8ooYWmWvfV
Janet Pope Janetbirdope ( View Tweet)
Hendrika Bootsma presents her ASAP III study- monocentre double blinded randomised controlled study of abatacept vs placebo also negative other than esspri response difference at w12 and w24. Extension phase study to w48 with US and histology results #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
No point on repeating ANA testing PPV 0.01 according to this abstract by Yeo et al. #EULAR2019 #Rheumatology @RheumNow https://t.co/kX0angBvqd
Sebastian C Rodriguez-García sdlcrodriguez ( View Tweet)
Full house in Jaki and beyond session. S Cohen presented fenebrutinib a BTK inhibitor at doses including 200 mg bid is in TNFI-IR or Mtx-IR active pts with RA in a Phase II RCT. 12 week data were similar to adalimumab. New pathway for RA Rx maybe #OP0025 https://t.co/avLSopLju6
Janet Pope Janetbirdope ( View Tweet)
Difficult to use existing “borrowed” conventional measures or essdai to measure change in the joint domain (most commonly affected) in abatacept study on primary Sjogren #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
Disappointing @tuna0sashimi: BMS abatacept 125mg wkly in Sjogren: essdai >=5 SSA+ primarily outcome mean change in essdai. Day 169 onwards open label. Negative study using these endpoints but some positive effect on serum IgG and complements. #eular2019 @RheumNow
Dr Irwin Lim _connectedcare ( View Tweet)
Fantastic talk by Georgios Filippou highlighting how we can use US to help us differentiate DDx and clinical phenotypes. #eular2019 @RheumNow https://t.co/hxKqrziDSN
Alberta Hoi tuna0sashimi ( View Tweet)
Empathic communication can help close the gap with patients - this is a learned skill - we need to work on it as a profession #empathy @HelenRiessMD @vmontori @JohnDavisIII @RheumNow @HealioRheum https://t.co/1pwn56o9lc
Leonard Calabrese LCalabreseDO ( View Tweet)
Romosozumab has dual effect: bone-forming AND preventing resorption. Hitting hard with this early in #osteoporosis reduces fracture risk later when on denosumab, compared to those receiving placebo prior. Similar results when patients switch to alendronate. @RheumNow #EULAR2019 https://t.co/ZSQAxSUnv9
Mrinalini Dey DrMiniDey ( View Tweet)